Back to Search
Start Over
Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers.
- Source :
-
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2021 Jan; Vol. 147 (1), pp. 205-212. Date of Electronic Publication: 2020 Jul 18. - Publication Year :
- 2021
-
Abstract
- Background: The anti-SLAMF7 monoclonal antibody, elotuzumab (elo), plus lenalidomide (len) and dexamethasone (dex) is approved for relapsed/refractory MM in the U.S. and Europe. Recently, a small phase 2 study demonstrated an advantage in progression-free survival (PFS) for elo plus pomalidomide (pom)/dex compared to pom/dex alone and resulted in licensing of this novel triplet combination, but clinical experience is still limited.<br />Purpose: To analyze the efficacy and safety of elo/pom/dex in a "real world" cohort of patients with advanced MM, we queried the databases of the university hospitals of Würzburg and Vienna.<br />Findings: We identified 22 patients with a median number of five prior lines of therapy who received elo/pom/dex prior to licensing within an early access program. Patients received a median number of 5 four-week treatment cycles. Median PFS was 6.4 months with 12-month and 18-month PFS rates of 35% and 28%, respectively. The overall response rate was 50% and 64% of responding patients who achieved a longer PFS with elo/pom/dex compared to their most recent line of therapy. Objective responses were also seen in five patients who had been pretreated with pomalidomide. Low tumor burden was associated with improved PFS (13.5 months for patients with ISS stage I/II at study entry v 6.4 months for ISS III), although this difference did not reach statistical significance. No infusion-related reactions were reported. The most frequent grade 3/4 adverse events were neutropenia and pneumonia.<br />Conclusion: Elo/pom/dex is an active and well-tolerated regimen in highly advanced MM even after pretreatment with pomalidomide.
- Subjects :
- Academic Medical Centers
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized administration & dosage
Dexamethasone administration & dosage
Female
Follow-Up Studies
Humans
Lenalidomide administration & dosage
Male
Middle Aged
Multiple Myeloma pathology
Prognosis
Remission Induction
Retrospective Studies
Survival Rate
Thalidomide administration & dosage
Thalidomide analogs & derivatives
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Multiple Myeloma drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1432-1335
- Volume :
- 147
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Journal of cancer research and clinical oncology
- Publication Type :
- Academic Journal
- Accession number :
- 32683487
- Full Text :
- https://doi.org/10.1007/s00432-020-03323-6